On December 21, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage biotechnology company committed to improving outcomes for people living with advanced immunological diseases, announced a licensing agreement between its affiliate, LE2025 Therapeutics AG, and Qyuns Therapeutics Co., Ltd. for the development and commercialization of WIN027 (also known as QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13.

Under the terms of the agreement, Windward Bio will gain exclusive rights to develop, manufacture, and commercialize WIN027 outside of China, for a total of up to USD 700 m in upfront and equity consideration and development and commercial milestones, as well as tiered royalties.

The Homburger team advising Windward Bio includes Andreas Müller, Margrit Marti, Timo Hasler and Lucas Forrer (all Healthcare / Life Sciences and Corporate / M&A), Stefan Oesterhelt and Juliette Buob (both Tax) and other subject matter specialists.

Contact

Gloria Pünchera / Marketing / [email protected]